ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1127

Real-World Use of SGLT2 Inhibitors in Patients with CKD with and without Diabetes: A Population-Based Cohort Study

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Toro, Luis, Universidad de Chile Facultad de Medicina, Santiago, Chile
  • Valderrama, Josefa, Universidad de Chile Facultad de Medicina, Santiago, Chile
  • Polanco, Diego, Universidad de Chile Facultad de Medicina, Santiago, Chile

Group or Team Name

  • NephroChile Initiative.
Background

Several studies have revealed cardiovascular and renal benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in chronic kidney disease (CKD). Recent studies indicate that SGLT2i are underutilized in real-world situations. This study aimed to assess the usage rates in primary care practices regarding SGLT2i use among CKD patients.

Methods

Observational study of CKD patients > 18 years (eGFR < 60 mL/min/1.73m2) in medical control in primary care facilities between January 2022 and December 2023. We included both patients with and without type 2 diabetes. We excluded patients with type 1 diabetes, polycystic kidney disease, and an initial eGFR < 20 mL/min/1.73m2. The study assessed the use of SGLT2i and analyzed variations in their usage through multivariate analysis.

Results

1,062 patients were included in the study. Age: 61.1±8.3 years. Female: 472 (44.4%). Diabetes: 254 (23.9%). CKD G3a: 504 (47.5%), G3b: 478 (45.0%), G4: 80 (7.5%). 690 (64.9%) had at least one urine albumin-to-creatinine ratio (uACR) measurement. Only 254 (23.9%) were using SGLT2i. Predictors of SGLT2i use included the presence of diabetes (OR: 6.1 [4.5-8.4]), at least one consultation with a nephrologist (OR: 5.0 [3.6-6.9]) or diabetologist (OR: 25.4 [16.9-37.8]), and at least one uACR measurement (OR: 17.1 [11.9-24.7]), regardless of the value (Figure 1). No significant differences were found in age, socioeconomic status, healthcare system, or cardiovascular risk factors.

Conclusion

The utilization rates of SGLT2i are notably low among CKD patients. The results suggest that patients managed by physicians who are more knowledgeable about current CKD guidelines are more likely to receive SGLT2i. These findings highlight significant opportunities to improve the use of SGLT2i, particularly in primary care settings, to prevent future adverse clinical outcomes.
Study supported by FONDECYT Regular 1221571.

Funding

  • Government Support – Non-U.S.